The PAN-PDE4 inhibitors rolipram, RS25344, and piclamilast/RP73401, all replicated the effect of roflumilast and elevated blood glucose levels (Figure 2A), thus confirming that transient hyperglycemia is a shared class effect of PDE4 inhibitors. This evidence concerns the gene PDE4A and Hyperglycemia.